Waoo Takes TV Authentication and Analytics to the Cloud with Verimatrix
15.4.2020 18:45:00 EEST | Business Wire | Press release
Verimatrix, (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, today announced that Waoo, Denmark's leading provider of internet, TV, streaming and telephony via the fiber network, has selected the Verimatrix Video Content Authority System (VCAS™) for IPTV, Verimatrix Multi-DRM and Verimatrix Analytics – all as software-as-a-service (SaaS) solutions. Lower capital investment and faster time-to-market through cloud-based services provide Waoo a competitive advantage in the Danish market.
“Unifying our security and analytics platforms with a single partner gives us better economies of scale along with streamlined management of the solutions – via the power of the cloud,” said Ole Ørndrup, CTO of Waoo. “We believe in the Verimatrix product roadmap to help future proof our networks and deliver the best experience for our subscribers.”
The cloud-based VCAS content and revenue security platform provides two-way protection for premium content on Waoo’s IPTV network, while Verimatrix Multi-DRM reduces complexity which allow the operator to retain full control of its service offerings and subscriber relationships. Cloud-native Verimatrix Analytics unifies data across Waoo’s IPTV and OTT networks and end devices to help optimize multi-network video service delivery and the subscriber viewing experience, which ultimately improves user engagement and increases revenue.
“We are pleased to extend our relationship with Waoo where we are helping the company take advantage of benefits of the SaaS model to streamline complexity, analytics and security,” said Asaf Ashkenazi, COO of Verimatrix. “With our flexible deployment options and strong partner ecosystem, Waoo is better able to offer a range of advanced services that meet their customers’ growing needs helping to maximize service revenue and ROI.”
The Verimatrix solutions are integrated with the Nordija fokusOn middleware solution and will be extended to set-top boxes and in-home WiFi equipment to maximize the business impact of the multi-network, multi-screen video intelligence platform.
Visit the Verimatrix website to learn more about VCAS, Verimatrix Multi-DRM and Verimatrix Analytics solutions or attend next week’s Verimatrix Virtual Summit. The online forum will present the news planned to be unveiled at NAB, in addition to providing participants with an in-depth product review and Q&A session immediately following. Visit our website to sign up to attend the kickoff webinar and schedule a private, 1-on-1 meeting: www.verimatrix.com/events/verimatrix-virtual-summit.
About Waoo
Waoo is Denmark's leading provider of entertainment and communication over fiber. Waoo's products on the internet, TV, streaming and telephony are provided by the local fiber network company, which also provides consulting, installation, support and customer service. For 8 consecutive years Waoo has been elected as Denmark’s best internet provider. Waoo Fiber has a speed guarantee, high stability and lots of capacity, so its products make it possible to realize the full potential of the internet. For more information visit www.waoo.dk
About Verimatrix
Verimatrix (Euronext Paris: VMX), formerly known as Inside Secure, is a global provider of innovative, customer-friendly cybersecurity solutions that protect content, devices, software and applications across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day. With more than 20 years of experience and the top minds in the industry, the company is uniquely positioned to understand and proactively anticipate security and business challenges for customers. Verimatrix partners to provide innovative, customer-friendly solutions that are cost-effective, easy to deploy and supported with responsive customer service teams based worldwide. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005049/en/
Contact information
Investor and media contacts
Investor Relations
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom